Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840

Bibliography

• DeCoursey TE, Chandy KG, Gupta S, Cahalan MD. Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis? Nature 1984;307:465-8
   PubMed Web of Science ®Google Scholar
• Matteson DR, Deutsch C. K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature 1984;307:468-71
   PubMed Web of Science ®Google Scholar
• Wulff H, Knaus HG, Pennington M, Chandy KG. K+ channel expression during B-cell differentiation: implications for immunomodulation and autoimmunity. J Immunol 2004;173:776-86
   PubMed Web of Science ®Google Scholar
• Mackenzie AB, Chirakkal H, North RA. Kv1.3 potassium channels in human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2003;285:L862-8
   Google Scholar
• Vicente R, Escalada A, Coma M, Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages. J Biol Chem 2003;278(47):46307-20
   Google Scholar
• Arkett SA, Dixon J, Yang JN, Mammalian osteoclasts express a transient potassium channel with properties of Kv1.3. Receptors Channels 1994;2:281-93
   PubMedGoogle Scholar
• Maruyama Y. A patch-clamp study of mammalian platelets and their voltage-gated potassium current. J Physiol 1987;391:467-85
   PubMed Web of Science ®Google Scholar
• Schlichter LC, Sakellaropoulos G, Ballyk B, Properties of K+ and Cl- channels and their involvement in proliferation of rat microglial cells. Glia 1996;17:225-36
   PubMed Web of Science ®Google Scholar
• Khanna R, Roy L, Zhu X, Schlichter LC. K+ channels and the microglial respiratory burst. Am J Physiol Cell Physiol 2001;280:C796-806
   PubMed Web of Science ®Google Scholar
• Pappone PA, Ortiz-Miranda SI. Blockers of voltage-gated K channels inhibit proliferation of cultured brown fat cells. Am J Physiol 1993;264:C1014-19
   PubMed Web of Science ®Google Scholar
• Chittajallu R, Chen Y, Wang H, Regulation of Kv1 subunit expression in oligodendrocyte progentitor cells and their role in G1/S phase progression of the cell cycle. Proc Natl Acad Sci USA 2002;99:2350-5
   Google Scholar
• Fadool DA, Levitan IB. Modulation of olfactory bulb neuron potassium current by tyrosine phosphorylation. J Neurosci 1998;18:6126-37
   PubMed Web of Science ®Google Scholar
• Fadool DA, Tucker K, Perkins R, Kv1.3 channel gene-targeted deletion produces “Super-Smeller Mice” with altered glomeruli, interacting scaffolding proteins, and biophysics. Neuron 2004;41:389-404
   PubMed Web of Science ®Google Scholar
• Chandy KG, Wulff H, Beeton C, Potassium channels as targets for specific immunomodulation. Trends Pharmacol Sci 2004;25:280-9
   PubMed Web of Science ®Google Scholar
• Lin CS, Boltz RC, Blake JT, Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J Exp Med 1993;177:637-45
   PubMed Web of Science ®Google Scholar
• Zhang SL, Yu Y, Roos J, STIM1 is a Ca2+ sensor that activates CRAC channels and migrates from the Ca2+ store to the plasma membrane. Nature 2005;437:902-5
   PubMed Web of Science ®Google Scholar
• Feske S, Gwack Y, Prakriya M, A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 2006;441:179-85
   PubMed Web of Science ®Google Scholar
• Vig M, Peinelt C, Beck A, CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. Science 2006;312:1220-3
   PubMed Web of Science ®Google Scholar
• Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol 2007;7:690-702
   PubMed Web of Science ®Google Scholar
• Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. Immunol Rev 2009;231:59-87
   PubMed Web of Science ®Google Scholar
• Cahalan MD, Chandy KG. Ion channels in the immune system as targets for immunosuppression. Curr Opin Biotechnol 1997;8:749-56
   PubMed Web of Science ®Google Scholar
• Wulff H, Calabresi PA, Allie R, The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. J Clin Invest 2003;111:1703-13
   PubMed Web of Science ®Google Scholar
• Beeton C, Wulff H, Standifer NE, Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 2006;103:17414-19
   PubMed Web of Science ®Google Scholar
• Matheu MP, Beeton C, Garcia A, Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 2008;29:602-14
   PubMed Web of Science ®Google Scholar
• Markovic-Plese S, Cortese I, Wandinger KP, CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest 2001;108:1185-94
   PubMed Web of Science ®Google Scholar
• Viglietta V, Kent SC, Orban T, Hafler DA. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest 2002;109:895-903
   PubMed Web of Science ®Google Scholar
• Kivisakk P, Mahad DJ, Callahan MK, Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol 2004;55:627-38
   PubMed Web of Science ®Google Scholar
• Rus H, Pardo CA, Hu L, The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci USA 2005;102:11094-9
   PubMed Web of Science ®Google Scholar
• Beeton C, Chandy KG. Potassium channels, memory T cells and multiple sclerosis. Neuroscientist 2005;11:550-62
   PubMed Web of Science ®Google Scholar
• Beeton C, Pennington MW, Wulff H, Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 2005;67:1369-81
   PubMed Web of Science ®Google Scholar
• Koo GC, Blake JT, Talento A, Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol 1997;158:5120-8
   PubMed Web of Science ®Google Scholar
• Valverde P, Kawai T, Taubman MA. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. J Bone Miner Res 2004;19:155-64
   PubMed Web of Science ®Google Scholar
• Beeton C, Wulff H, Barbaria J, Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 2001;98:13942-7
   PubMed Web of Science ®Google Scholar
• Koo GC, Blake JT, Shah K, Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol 1999;197:99-107
   PubMed Web of Science ®Google Scholar
• Schmitz A, Sankaranarayanan A, Azam P, Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T Cells in autoimmune diseases. Mol Pharmacol 2005;68:1254-70
   PubMed Web of Science ®Google Scholar
• Azam P, Sankaranarayanan A, Homerick D, Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 2007;127:1419-29
   PubMed Web of Science ®Google Scholar
• Hyodo T, Oda T, Kikuchi Y, Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular dasement membrane glomerulonephritis. Am J Physiol Renal Physiol 2010. [Epub ahead of print]
   Google Scholar
• Ren YR, Pan F, Parvez S, Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS ONE 2008;3:e4009
   PubMed Web of Science ®Google Scholar
• Gilhar A, Bergman R, Assay B, The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model. J Invest Dermatol 2010. [Epub ahead of print]
   Google Scholar
• Xu J, Koni PA, Wang P, The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight. Hum Mol Gen 2003;12:551-9
   PubMed Web of Science ®Google Scholar
• Xu J, Wang P, Li Y, The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. Proc Natl Acad Sci USA 2004;101:3112-17
   PubMed Web of Science ®Google Scholar
• Tucker K, Overton JM, Fadool DA. Kv1.3 gene-targeted deletion alters longevity and reduces adiposity by increasing locomotion and metabolism in melanocortin-4 receptor-null mice. Int J Obes (Lond) 2008;32:1222-32
   PubMed Web of Science ®Google Scholar
• Solvay Pharmaceuticals GMBH. Methods of using potassium channel inhibiting compounds. WO2007020286 A2; 2007
   Google Scholar
• Michne W, Guiles J, Treasurywala A, Novel inhibitors of potassium ion channels on human T lymphocytes. J Med Chem 1995;38:1877-83
   PubMed Web of Science ®Google Scholar
• Hill RJ, Grant AM, Volberg W, WIN 17317-3: novel nonpeptide antagonist of voltage-activated K+ channels in human T lymphocytes. Mol Pharmacol 1995;48:98-104
   PubMed Web of Science ®Google Scholar
• Nguyen A, Kath JC, Hanson DC, Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation. Mol Pharmacol 1996;50:1672-9
   PubMed Web of Science ®Google Scholar
• Burgess LE, Kock K, Cooper K, The SAR of UK-78,282: a novel blocker of human T cell Kv1.3 potassium channels. Bioorg Med Chem Lett 1997;7:1047-52
   Google Scholar
• Hanson DC, Nguyen A, Mather RJ, UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation. Br J Pharmacol 1999;126:1707-16
   PubMed Web of Science ®Google Scholar
• Goetz MA, Hensens OD, Zink DL, Potent nor-triterpenoid blockers of the voltage-gated potassium channel Kv1.3 from Spachea correae. Tetrahedron Lett 1998;39:2895-8
   Google Scholar
• Felix JP, Bugianesi RM, Schmalhofer WA, Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry 1999;38:4922-30
   Google Scholar
• Hanner M, Schmalhofer WA, Green B, Binding of correolide to Kv1 family potassium channels. J Biol Chem 1999;274:25237-44
   PubMed Web of Science ®Google Scholar
• Schmalhofer WA, Bao J, McManus OB, Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties. Biochemistry 2002;18:7781-94
   Google Scholar
• Miao S, Bao J, Garcia ML, Benzamide derivatives as blockers of the Kv1.3 ion channel. Bioorg Med Chem Lett 2003;13:1161-4
   Google Scholar
• Baell JB, Gable RW, Harvey AJ, Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J Med Chem 2004;47:2326-36
   PubMed Web of Science ®Google Scholar
• Harvey AJ, Baell JB, Toovey N, A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. J Med Chem 2006;49:1433-41
   PubMedGoogle Scholar
• Bionomics Ltd, Australia. Novel benzofuran potassium channel blockers and uses thereof. WO2008040057; 2008
   Google Scholar
• Bionomics Ltd, Australia. Novel chromenone potassium channel blockers and uses thereof. WO2008040058; 2008
   Google Scholar
• Bionomics Ltd, Australia. Novel aryl potassium channel blockers and uses thereof. WO2009043117; 2009
   Google Scholar
• Amgen. Fusion proteins of toxin peptides with linkers and IgG and their use as therapeutic agents. WO2006116156; 2006
   Google Scholar
• Mouhat S, Visan V, Ananthakrishnan S, K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem J 2005;385:95-104
   PubMed Web of Science ®Google Scholar
• Wulff H, Zhorov BS. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev 2008;108:1744-73
   PubMed Web of Science ®Google Scholar
• Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 2009;8:982-1001
   PubMed Web of Science ®Google Scholar
• Vianna-Jorge R, Oliveira C, Garcia M, Correolide, a nor-triterpenoid blocker of shaker-type Kv1 channels elicits twitches in guinea-pig ileum by stimulating the enteric nervous system and enhancing neurotransmitter release. Br J Pharmacol 2000;131:772-8
   Google Scholar
• Vianna-Jorge R, Oliveira CF, Garcia ML, Shaker-type Kv1 channel blockers increase the peristaltic activity of guinea-pig ileum by stimulating acetylcholine and tachykinins release by the enteric nervous system. Br J Pharmacol 2003;138:57-62
   Google Scholar
• Nguyen W, Howard BL, Neale DS, Use of Kv1.3 blockers for inflammatory skin conditions. Curr Med Chem 2010;17:2882-96
   Google Scholar